A powerful, real-world evidence study designed by McKesson for its biopharma partner played a key role in the Food and Drug Administration’s (FDA) approval for first-line indication for a rare disease.
Share
Real-World Evidence from McKesson Supports First-Ever FDA Approval for Metastatic Merkel Cell Carcinoma Drug
A powerful, real-world evidence study designed by McKesson for its biopharma partner played a key role in the Food and Drug Administration’s (FDA) approval for first-line indication for a rare disease.